vimarsana.com

Latest Breaking News On - Michael krepps - Page 1 : vimarsana.com

Krepps makes difference no matter what role

Whether as a teacher, school administrator, municipal politician, church leader or community volunteer, Michael Krepps always seems to take on the role of a doer.

United statesMichael kreppsConneaut lake presbyterian churchCrawford county planning commissionConneaut lake community development committeeConneaut lake borough councilCommunity churchJamestown high schoolTrinity methodist churchJamestown school districtCommunity church at conneaut lakeConneaut lakeHis workConneaut lake areaWork his wayHigh street community church

OncoPep to Present Clinical and Pipeline Update to Investors at BioTech Showcase 2023

/PRNewswire/ OncoPep, Inc. is proud to be a presenter at this year s Biotech Showcase January 9-11 in San Francisco. The company will be sending members of.

United kingdomSan franciscoUnited statesMichael kreppsOncopep incBiotech showcaseChief operating officer michael kreppsChief strategy officer jaehan

Dr Victor Moyo, MBChB, Joins OncoPep as Chief Medical Officer

/PRNewswire/ OncoPep, Inc. has named Dr. Victor Moyo Chief Medical Officer effective May 9th. As CMO, Moyo will provide strategic clinical leadership to.

United kingdomJohn hopkinsMichael kreppsVictor moyoGeorge washington university hospitalOncopep incMerrimack incUniversity of zimbabweL eaf pharmaceuticalsVictor moyo chief medical officerChief operating officer

OncoPep Completes $11 Million Series D Financing to Continue Clinical Trials and Advance Pipeline Development

/PRNewswire/ OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera.

United statesUnited kingdomKendall squareChristopher bahlMichael kreppsKukje pharmaDennis klinmanNational cancer instituteInflammation program immune modulation sectionSx companyDartmouth universityUniversity of pennsylvaniaOncopep incUniversity of maineInstitute for protein innovationTera science

OncoPep Completes $11 Million Series D Financing to Continue Clinical Trials and Advance Pipeline Development

/PRNewswire/ OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera.

United statesUnited kingdomKendall squareChristopher bahlMichael kreppsKukje pharmaDennis klinmanNational cancer instituteInflammation program immune modulation sectionSx companyDartmouth universityUniversity of pennsylvaniaOncopep incUniversity of maineInstitute for protein innovationTera science

vimarsana © 2020. All Rights Reserved.